PPCB — Propanc Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517681 ·
Last close
$0.63
Market Cap
$1.44M
52W High
$52.50
52W Low
$0.56
ADV30
3,614,983
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,400,221 | -6,360,336 | 14,333,780 | 443,702 | 3,505,895 |
| Dec 2025 | 0 | — | -3,654,734 | -3,091,394 | 15,111,532 | 561,237 | 3,659,267 |
| Sep 2025 | 0 | — | -4,673,564 | -4,837,738 | 17,975,681 | 602,737 | 3,614,514 |
| Jun 2025 | 0 | — | -3,645,246 | -4,071,461 | 19,631,808 | 12,088 | 5,725,616 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,176,849
Investing CF
$-4,912
Financing CF
$4,620,970
CapEx
$-4,912
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-336.75
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-140,843,234
Inventory
—
Receivables
$11,057
ST Investments
—
EBIT TTM
$-67,849,898
Pretax Income TTM
$-68,356,814
Interest Exp TTM
$506,916
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 0 | -1,536,049 | -1,820,528 | 72,365 | 3,851,424 | -3,779,059 | -935,118 |
| Jun 2023 | 0 | -1,776,645 | -2,660,566 | 60,328 | 3,177,507 | -3,117,179 | -1,105,251 |
| Jun 2022 | 0 | -1,990,870 | -2,658,087 | 81,651 | 3,105,300 | -3,023,649 | -1,436,304 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $1.40M | $0.77 | — |
| LIFD | LFTD PARTNERS INC. | $1.48M | $0.10 | — |
| GCAN | TRAFALGAR INTERNATIONAL, INC. | $1.60M | $1.61 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $1.65M | $0.50 | — |
News headlines (Yahoo Finance, 1h cache)
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
2026-09-22 12:30 · Yahoo
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
2026-09-16 12:30 · Yahoo
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
2026-09-09 12:30 · Yahoo
Propanc Biopharma Reports PRP Preclinical Pancreatic Cancer Data Showing Over 90% Tumor Growth Inhibition
2026-08-27 14:29 · Yahoo
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
2026-08-27 12:30 · Yahoo
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
2026-08-06 12:30 · Yahoo
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
2026-08-05 12:30 · Yahoo
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
2026-07-21 12:30 · Yahoo
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
2026-07-07 12:30 · Yahoo
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
2026-07-02 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.